Zobrazeno 1 - 10 of 56 pro vyhledávání: '"Leslie B. Tyson"'
1
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
Autor: Lee M. Krug, Maria Catherine Pietanza, Naoko Takebe, Rosalyn A. Juergens, Mark G. Kris, Sara Subzwari, Naiyer A. Rizvi, Andrew Brown, William D. Travis, Paul K. Paik, Leonard James, Charles M. Rudin, Michelle S. Ginsberg, Susan Markus, Leslie B. Tyson
Publikováno v: Lung Cancer. 74:481-485
We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31cf5a5e55ed8ad4b1e121b90bc91dd
https://doi.org/10.1016/j.lungcan.2011.05.005
Zobrazit plný text záznamu
2
Putting Evidence Into Practice®: Evidence-Based Interventions for Cancer-Related Dyspnea
Autor: Ann E. Culkin, Leslie B. Tyson, W. M. Disalvo, Kathleen Mackay, Margaret M. Joyce
Publikováno v: Clinical Journal of Oncology Nursing. 12:341-352
Despite the common occurrence of cancer-related dyspnea, a paucity of literature is available for review, especially research literature that reports interventions to control dyspnea. The Oncology Nursing Society’s Putting Evidence Into Practice®
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f313868c942eb008bd5cabe15509acbf
https://doi.org/10.1188/08.cjon.341-352
Zobrazit plný text záznamu
3
A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer
Autor: Lee M. Krug, Barbara Coleman, Barbara Pizzo, Lauren Lastinger, Teresa Seeger, Christopher G. Azzoli, Amy Farmer, Charles M. Rudin, Mark G. Kris, Erin Moore, Naiyer A. Rizvi, Vincent A. Miller, Leslie B. Tyson, Ennapadam Venkatraman, Megan Dunne
Publikováno v: Journal of Thoracic Oncology. 2(7):638-644
Introduction We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer. Methods The primary endpoint was amount of cisplatin deliv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891e53ed38a5ccd86ac88ba9a6be5ea6
Zobrazit plný text záznamu
5
Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib
Autor: William Pao, Vincent A. Miller, Murk-Hein Heinemann, Mark G. Kris, Barbara Pizzo, Dana L. Sachs, Leah Ben-Porat, Leslie B. Tyson, Robert T. Heelan, Neelam T. Shah
Publikováno v: Journal of Clinical Oncology. 23:165-174
Purpose The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of acti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::282440648706564eea3e48f7ffae5468
https://doi.org/10.1200/jco.2005.04.057
Zobrazit plný text záznamu
7
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
Autor: Barbara Pizzo, Manreen Zakowski, Ennapadam Venkatraman, Lee M. Krug, William Pao, Valerie W. Rusch, Vincent A. Miller, Natalie Memoli, Jyoti D. Patel, Naiyer A. Rizvi, Leslie B. Tyson, Christopher G. Azzoli, Mark G. Kris, Neelain Shah, Jorge Gomez, Robert T. Heelan, Leah Ben-Porat
Publikováno v: Journal of Clinical Oncology. 22:1103-1109
Purpose Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, induces radiographic regressions and symptomatic improvement in patients with non–small-cell lung cancer (NSCLC). Phase II trials suggested female sex and aden
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afc026c1013f6375857f96f0a75ded0d
https://doi.org/10.1200/jco.2004.08.158
Zobrazit plný text záznamu
8
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial
Autor: Binsheng Zhao, Camelia S. Sima, Kai Hsiung Lin, Dyana K. Sumner, Michelle S. Ginsberg, Lauren J. Rogak, M. Catherine Pietanza, Alison Berkowitz-Hergianto, Marwan Shouery, Samantha Lindsay Kass, Mark G. Kris, Ethan Basch, Aaron Gabow, Mary Shaw, Lawrence H. Schwartz, Alex E. Lash, Manda Wilson, Marcia Latif, Leslie B. Tyson, Qinfei Wu, Claire Miller
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(16)
Purpose In clinical trials, traditional monitoring methods, paper documentation, and outdated collection systems lead to inaccuracies of study information and inefficiencies in the process. Integrated electronic systems offer an opportunity to collec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dafdf707f7606da5309e6b7c79292ea1
https://pubmed.ncbi.nlm.nih.gov/23630218
Zobrazit plný text záznamu
9
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin
Autor: Lorraine Baltzer Cleri, Leslie B. Tyson, Rebecca A. Clark, Katherine M.W. Pisters, Richard J. Gralla, Mark G. Kris
Publikováno v: Cancer. 76:774-778
Background. Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting. In
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6507f7f577fd0f8b961f419c8eb9ae15
https://doi.org/10.1002/1097-0142(19950901)76:5<774::aid-cncr2820760510>3.0.co
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje